Grifols, Green Cross Corporation | July 21, 2020
Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million.
The transaction is part of Grifols' sustainable global growth strategy to expand plasma collection and fractionation capacity to ensure patients worldwide have safe and secure access to life-saving plasma-derived medicines. Most importantly, this strategic acquisition will strengthen Grifols' presence in Canada, building on a legacy of partnership in Canada's blood system.
For more than three decades, Grifols has been a fractionator of Canadian plasma under contract manufacturing services, providing trusted plasma-derived medicines for Canadian patients and their healthcare providers. Throughout these many years Grifols has gained firsthand knowledge of the Canadian healthcare system. This transaction further demonstrates Grifols' commitment to supporting domestic self-sufficiency and security of plasma-protein-product supply.
pharmiweb | April 15, 2019
Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding. Grifols is working to enhance the lives of the roughly 100,000 people around the world who have hemophilia but receive little or no treatment. The company is halfway into an eight-year initiative in which it has pledged a minimum of 200 million IUs to the World Federation of Hemophilia (WFH) Humanitarian Aid Program through 2021. According to the WFH, Grifols full donations will secure a projected average of 10,300 doses to treat acute bleeds in 6,000 patients per year in developing regions through 2021. Over the last two years, these donations have treated more than 5,000 patients and more than 10,000 acute bleeds. "World Hemophilia Day reminds us that there are tens of thousands of people who live with hemophilia in many countries and don't have access to care and treatment," said Victor Grifols Deu, co-CEO of Grifols. "Here at Grifols we're proud to partner with the WFH in its dedication to helping ensure that hemophilia patients in developing regions receive critical and often life-saving medicines. It's about people helping people." The company has also created the Grifols Humanitarian Awards in Hemophilia to encourage health care providers, medical and paramedical centers as well as hemophilia societies to support education and access to treatment for the approximately 400,000 people in developed and developing regions who have this inherited condition. Celebrating the first edition of the award, Grifols will award four €50,000 grants to eligible proposals, naming the recipients in early 2020. The Grifols Humanitarian Awards complement the company's Martín Villar Hemostasis Awards that support the investigation of hemophilia and von Willebrand disease. Since establishing this award in 2007, Grifols has conferred approximately €640,000 euros to 28 researchers.
khn.org | March 14, 2018
A program to give naloxone overdose-antidote kits and training to front-line officers. Funding for pill disposal boxes in pharmacies, clinics and police stations across North Carolina. A radio campaign in Connecticut warning of the dangers of opioid abuse. A new medicine to treat opioid-induced constipation. The money behind these efforts to combat the opioid epidemic and its side effects comes from a perhaps unlikely sponsor: Purdue Pharma, the company that makes the top-selling opioid, OxyContin.